Spero Therapeutics FY2025 net income swings to $8.6 million; revenue rises 39.2% to $66.8 million

Reuters03-27 04:07
Spero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net income swings to $8.6 million; revenue rises 39.2% to $66.8 million
  • Spero published its annual report on Form 10-K, reporting total revenues of USD 66.8 million and net income of USD 8.6 million.
  • Grant revenue fell 65.1% to USD 7.2 million, primarily due to lower BARDA funding following the conclusion of the Phase 3 trial for tebipenem HBr and reduced NIAID-qualified expenses after SPR206 development was halted and the contract was terminated.
  • Collaboration revenue from GSK rose 74% to USD 47 million, including USD 25 million recognized upon GSK’s NDA filing for tebipenem HBr in December 2025.
  • Research and development expense declined 60.3% to USD 38.5 million, reflecting decreased clinical activity after the Phase 3 PIVOT-PO trial met its primary endpoint and was stopped early for efficacy, as well as reduced spending on SPR720 and SPR206 following program terminations.
  • Cash and cash equivalents were USD 40.3 million, and management said this is expected to fund operating expenses and required capital expenditures into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-126192), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment